EpCAM is not a LAIR-1 ligand! [1]

Cancer Biology and Therapy

Volumn 4, Issue 4, 2005, Pages 357-

  Nechansky, Andreas ^a   Kircheis, Ralf ^a  

^a Igeneon Krebs Immuntherapie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; HYBRID PROTEIN; IMMUNOGLOBULIN RECEPTOR; ISOPROTEIN; LEUKOCYTE ASSOCIATED IMMUNOGLOBULIN LIKE RECEPTOR 1; LIGAND; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

BINDING AFFINITY; CELL INTERACTION; GENETIC TRANSFECTION; IMMUNOSURVEILLANCE; LETTER; METASTASIS; PROTEIN FAMILY; PROTEIN INTERACTION; TUMOR CELL; TUMOR GROWTH;

EID: 25144511942     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.4.1661     Document Type: Letter

References (3)

1. Armstrong A, Eck SL. EpCAM. A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003; 2:320-6.
2. Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH, Clevers H. The epithelial cellular adhesion molecule (EpCAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR). J Exp Med 2001; 194:107-12.
3. Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH, Clevers H. Retraction. J Exp Med 2003; 198:1129.